Concise Review: Mesenchymal Stem Cells for Acute Lung Injury: Role of Paracrine Soluble Factor

Jae W Lee, Xiaohui Fang, Anna Krasnodembskaya, James P Howard, Michael A Matthay

Research output: Contribution to journalArticlepeer-review

293 Citations (Scopus)
172 Downloads (Pure)


Morbidity and mortality have declined only modestly in patients with clinical acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), despite extensive research into the pathophysiology. Current treatment remains primarily supportive with lung-protective ventilation and a fluid conservative strategy. Pharmacologic therapies that reduce the severity of lung injury in preclinical models have not yet been translated to effective clinical treatment options. Consequently, further research in translational therapies is needed. Cell-based therapy with mesenchymal stem cells (MSCs) is one attractive new therapeutic approach. MSCs have the capacity to secrete multiple paracrine factors that can regulate endothelial and epithelial permeability, decrease inflammation, enhance tissue repair, and inhibit bacterial growth. This review will focus on recent studies, which support the potential therapeutic use of MSCs in ALI/ARDS, with an emphasis on the role of paracrine soluble factors.
Original languageEnglish
Pages (from-to)913-919
Number of pages7
JournalStem Cells
Issue number6
Early online date23 May 2011
Publication statusPublished - Jun 2011

Bibliographical note

Copyright © 2011 AlphaMed Press.


Dive into the research topics of 'Concise Review: Mesenchymal Stem Cells for Acute Lung Injury: Role of Paracrine Soluble Factor'. Together they form a unique fingerprint.

Cite this